Aldeyra Therapeutics, based in the United States, is a pharmaceutical company with a Risk Rating Score of 29.3, indicating a medium level of risk. Specializing in next-generation medicines for immune-mediated diseases, their leading product, reproxalap, targets dry eye disease and allergic conjunctivitis. With a focus on ESG principles, Aldeyra Therapeutics is also developing treatments for a range of other conditions, including retinal diseases, autoimmune disorders, and cancer.